Skip to main content
Terug
RGC logo

Regencell Bioscience Holdings Limited

Datakwaliteit: 100%
RGC
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
€ 24,43
▼ € 0,79 (-3,13%)
Marktkapitalisatie: 12,08B
Dagbereik
€ 24,23 € 25,55
52-Weeksbereik
€ 0,55 € 83,60
Volume
52.519
50D / 200D Gem.
€ 28,38 / € 20,03
Vorige Slotkoers
€ 25,22

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -3369,8 0,4
P/B 2485,0 2,9
ROE % -54,8 3,7
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Belangrijkste Punten

Debt/Equity of 0,11 — conservative balance sheet
Negative free cash flow of -3,27M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-54,81%
ROIC-52,32%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,11
Current Ratio7,39
Interest Coverage0,00

Waardering

P/E Ratio
-3369,75
P/B Ratio2485,02
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -3,58M
ROE -54,81% ROA -62,27%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,27M
ROIC -52,32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,11 Current Ratio 7,39
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -3369,75 P/B Ratio 2485,02
P/S Ratio N/A PEG Ratio 136,35
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 12,08B Enterprise Value 12,08B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -3,58M -4,30M -5,87M -7,42M -1,35M
EPS (Diluted) -0,01 -0,01 -0,01 -0,02 0,00
Gross Profit -392.743,0 -745.588,0 -769.687,0 -604.397,0 -26.456,0
Operating Income -3,77M -4,74M -6,27M -7,62M -1,38M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5,76M 8,44M 12,62M 18,02M 340.134,0
Total Liabilities 895.308,0 219.512,0 632.320,0 938.032,0 4,34M
Shareholders' Equity 4,86M 8,22M 12,03M 17,07M -4,00M
Total Debt 544.415,0 85.741,0 463.669,0 771.255,0 3,68M
Cash & Equivalents 2,42M 2,96M 1,56M 6,42M 59.413,0
Current Assets 4,90M 8,11M 11,62M 16,44M 66.849,0
Current Liabilities 663.673,0 193.578,0 606.914,0 577.764,0 4,34M